Rituximab in recurrent idiopathic giant cell myocarditis after heart transplantation: A potential therapeutic approach

Transplant International

Volumn 27, Issue 5, 2014, Pages

  Toscano, Giuseppe ^a   Tartaro, Pietro ^a   Fedrigo, Marny ^a   Angelini, Annalisa ^a   Marcolongo, Renzo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

giant cell myocarditis; heart transplantation; immunosuppressive therapy; myocarditis; rituximab

Indexed keywords

AZATHIOPRINE; CD68 ANTIGEN; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; RITUXIMAB; TROPONIN I; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CD3+ T LYMPHOCYTE; CONTINUOUS HEMOFILTRATION; DISEASE SEVERITY; DRUG PULSE THERAPY; DYSPNEA; EOSINOPHIL; EXTRACORPOREAL OXYGENATION; FEMALE; FOLLOW UP; GIANT CELL MYOCARDITIS; HEART FAILURE; HEART FUNCTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MYOCARDITIS; NECROSIS; PRIORITY JOURNAL; REMISSION; RESUSCITATION; TREATMENT DURATION; GIANT CELL; IMMUNOLOGY; PATHOLOGY; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; FEMALE; GIANT CELLS; HEART TRANSPLANTATION; HUMANS; MYOCARDITIS; RECURRENCE;

EID: 84898772690     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12270     Document Type: Article

References (20)

1. Cooper LT Jr, Berry GJ, Shabetai R,. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997; 336: 1860.
2. Cooper LT Jr, ElAmm C,. Giant cell myocarditis. Diagnosis and treatment. Herz 2012; 37: 632.
3. Cooper LT Jr, Hare JM, Tazelaar HD, et al,. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102: 1535.
4. Caforio AL, Tona F, Fortina AB, et al,. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4: 962.
5. Specks U,. Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med 2012; 79 (Suppl. 3): S50.
6. Geetha D, Seo P,. Advances in therapy for ANCA-associated vasculitis. Curr Rheumatol Rep 2012; 14: 509.
7. Langford CA,. Update on the treatment of granulomatosis with polyangiitis (Wegener's). Curr Treat Options Cardiovasc Med 2012; 14: 164.
8. Brihaye B, Aouba A, Pagnoux C, Vignaux O, Le Hello C, Guillevin L,. Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. Presse Med 2008; 37 (3 Pt 1): 412.
9. Belkhou A, Younsi R, El Bouchti I, El Hassani S,. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 2008; 75: 511.
10. Gõmez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X,. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev 2012; 11: 646. Review.
11. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, et al,. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39: 125.
12. Rosenstein ED, Zucker MJ, Kramer N,. Giant cell myocarditis: most fatal of autoimmune diseases. Semin Arthritis Rheum 2000; 30: 1. Review.
13. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M,. Diagnosis, treatment and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6: 15.
14. Blauwet LA, Cooper LT,. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18: 733.
15. Scott RL, Ratliff NB, Starling RC, Young JB,. Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant 2001; 20: 375.
16. Cooper L, Orellana V, Schultheiss H-P, et al,. Long term risk of death, transplantation, and disease recurrence in giant cell myocarditis. J Am Coll Cardiol 2012; 59: E1547. (Abstract).
17. Litovsky SH, Burke AP, Virmani R,. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996; 9: 1126.
18. Menghini VV, Savcenko V, Olson LJ, et al,. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc 1999; 74: 1221.
19. Aggarwal P, Singh S, Suri D, Rawat A, Narula N, ManojKumar R,. Rituximab in childhood lupus myocarditis. Rheumatol Int 2012; 32: 1843.
20. Gottenberg J-E, Guillevin L, Lambotte O, et al,. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 920.